UroGen Plots Expansion, Brings In A New Asset

The company acquired a next-generation oncolytic virus from IconOVir that it plans to develop as a locally administered therapy for bladder cancer.

(Shutterstock)
Key Takeaways

UroGen acquired an oncolytic virus, ICVB-1042, from IconOVir Bio at an attractive price – just $4m upfront in equity.

The company plans to develop ICVB-1042 to be a locally administered therapy for bladder cancer and other cancers.

UroGen’s top priority remains getting UGN-102, now under FDA review, to market, CEO Liz Barrett said.

As UroGen prepares to bring a second drug to market later this year, the company is also expanding its early pipeline for long-term expansion

UroGen plans to develop ICVB-1042 to be a locally administered therapy for bladder cancer and other cancers, fitting with the

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deals

Pharma Left Hanging After US/UK Trade Pact

 
• By 

An ‘historic economic prosperity deal’ does not include the sector.

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By 

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

 
• By 

Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.

Lilly And Alchemab Tap Into Resilient Individuals To Develop ALS Drug

 

The pharma company is helping to validate the biotech’s model by developing a novel amyotrophic lateral sclerosis candidate, based on its novel approach that ‘turns drug discovery on its head’.

More from Strategy